<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52117">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02104830</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-017-3</org_study_id>
    <nct_id>NCT02104830</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Cancer Patients</brief_title>
  <official_title>International Multicenter Randomized Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of a Single Dose Extimia® Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BCD-017-3 is an double-blind randomized phase III clinical study to compare the incidence
      of CTCAE grade 3/4 neutropenia after a single administration  of recombinant human pegylated
      filgrastim empegfilgrastim (Extimia®)  at a dose of 6 or 7,5 mg versus daily administration
      of filgrastim  at a dose of 5 μg/kg/day for neutropenia prophylaxis in breast cancer
      patients  receiving myelosuppressive chemotherapy.

      The study also includes the following determination of pharmacokinetic parameters after
      repeated administration of the study drug.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Duration of  neutropenia CTCAE grade 4</measure>
    <time_frame>3 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia® versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of grade 4 neutropenia from the 2nd to 4th cycles;</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of severe neutropenia (grade 3-4)</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Chemotherapy-induced Neutropenia</condition>
  <arm_group>
    <arm_group_label>Empegfilgrastim 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empegfilgrastim 7,5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single administration of empegfilgrastim at a dose of 7,5 mg subcutaneously, 24 h after the chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Filgrastim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive filgrastim at a dose of   5 μg/kg subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo №1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a single administration of placebo №1 at a dose of 1 ml subcutaneously, 24 h after the chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo №2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive placebo №2 subcutaneously daily (until ANC 10 000/μL or for 14 days, whichever occurred first), starting 24 h after the chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>empegfilrastim 6 mg</intervention_name>
    <description>Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.</description>
    <arm_group_label>Placebo №2</arm_group_label>
    <other_name>Extimia</other_name>
    <other_name>metpegfilgrastim</other_name>
    <other_name>pegylated filgrastim</other_name>
    <other_name>peg-GCSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.</description>
    <arm_group_label>Placebo №1</arm_group_label>
    <other_name>GCSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo №1</intervention_name>
    <arm_group_label>Filgrastim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo №2</intervention_name>
    <arm_group_label>Empegfilgrastim 6 mg</arm_group_label>
    <arm_group_label>Empegfilgrastim 7,5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>empegfilrastim 7,5 mg</intervention_name>
    <description>Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.</description>
    <arm_group_label>Placebo №2</arm_group_label>
    <other_name>Extimia</other_name>
    <other_name>metpegfilgrastim</other_name>
    <other_name>pegylated filgrastim</other_name>
    <other_name>peg-GCSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form;

          -  Histologically verified diagnosis of stage IIb/III/IV breast cancer;

          -  Age of 18-70 years inclusive;

          -  Life expectancy of at least 6 months after  inclusion in the study;

          -  If the patient had received the chemotherapy for breast cancer, it should be finished
             30 days before the beginning of the study;

          -  ECOG Performance Status of 0- 2, not increasing within during 2 weeks before
             randomization;

          -  ANC level of 1500/μL and more at the beginning of the study

          -  Platelet count of 100 000/μL and more at the beginning of the study

          -  Hemoglobin level of 90 g/l and more

          -  Creatinine level &lt;1.5 mg/dl

          -  Total bilirubin level &lt;1.5 × the upper limit of normal (ULN)

          -  ALT and/or AST levels &lt;2.5×ULN (5×ULN for patients with liver metastases);

          -  Alkaline phosphatase &lt;5×ULN;

          -  Left ventricular ejection fraction &gt;50% and more;

          -  If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose
             of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for
             epirubicin,if in this study planned 6 cycles of chemotherapy ;

          -  If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose
             of anthracyclines should not exceed 350 mg/m2 for doxorubicin or 660 mg/m2 for
             epirubicin,if in this study planned 4 cycles of chemotherapy ;

          -  Ability of the participant to follow the protocol requirements, according to the
             Investigator's opinion;

          -  Patients of childbearing potential must implement reliable contraceptive measures
             during the study treatment, starting 4 weeks prior randomization and for 6 months
             after the last administration of the study drug;

          -  Patients should be able to follow the Protocol procedures (according to
             Investigator's assessment.

        Exclusion Criteria:

          -  Patient has received two or more chemotherapy regimens for the metastatic breast
             cancer;

          -  Documented hypersensitivity to filgrastim, pegfilgrastim, docetaxel, doxorubicin,
             dexamethasone and/or its excipients, PEGylated drugs, recombinant proteins.

          -  Pregnancy or breastfeeding;

          -  Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim
             administration;

          -  Concomitant radiotherapy (except selective radiotherapy of bone metastases);

          -  Surgery, radiotherapy (except selective radiotherapy of bone metastases),
             administration of any experimental drugs within 30 days prior randomization;

          -  History of bone marrow/stem cell transplantation;

          -  Conditions limiting the patient's ability to follow the protocol;

          -  CTCAE grade 3-4 neuropathy;

          -  HIV, HCV, HBV, T.Pallidum infection(s);

          -  Acute or active chronic infections;

          -  Severe concurrent diseases (for example, severe arterial hypertension, severe heart
             failure, and other);

          -  Severe depression, schizophrenia, any other mental disorders;

          -  Obstacles in intravenous administration of study drugs;

          -  Simultaneous participation in other clinical trials, previous participation in other
             clinical trials within 30 days before entering into the trial, previous participation
             in the same trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Biocad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larisa Bolotina, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Institution &quot;Moscow Research Oncological Institute P.A.Gertsena &quot;of the Ministry of Health of the Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Brichkova, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Regional Oncology Dispensary №1</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Burdaeva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health Arkhangelsk region &quot;Arkhangelsk Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Byakhov Michael, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Non-governmental healthcare institution &quot;Central Clinical Hospital № 2 Semashko&quot; JSC &quot;Russian Railways&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir Vladimirov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health Stavropol area &quot;Piatigorsky Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rinat Galiulin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State budget healthcare institution Omsk region &quot;Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oleg Gladkov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health &quot;Chelyabinsk Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irina Davydenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health &quot;Clinical Oncology Dispensary № 1&quot; of the Ministry of Health of the Krasnodar area</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victoria Elkova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Voronezh Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Lifirenko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Kursk Regional Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadezhda Kovalenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health &quot;Volgograd regional oncologic dispensary № 3&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kopp, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health &quot;Samara Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bogdan Kotiv, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Military Medical Academy named after S.M. Kirov</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Natalia Levchenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution of Health Stavropol area &quot;Stavropol Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marina Matrosova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Nizhny Novgorod Regional Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guzel Mukhametshina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Republican Clinical Oncology Dispensary&quot; of the Ministry of Health of the Republic of Tatarstan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergei Panchenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State public health institution &quot;Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Pecheny, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Regional State Health Care Institution &quot;Orlovsky Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Pimenov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Budget Institution health care &quot;Tula Regional Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei Sinykov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution of Tyumen Region &quot;Regional Oncological Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pavel Skopin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Educational Institution of Higher Professional Education &quot;Mordovia State University N.P. Ogareva &quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniil Stroyakovsky</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution &quot;Moscow City Oncology Hospital № 62&quot; Moscow Health Department</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergei Tyulyandin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Russian Oncological Scientific Center N.N.Blokhin&quot; Russian Academy of Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dmitriy Udovica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution  &quot;Oncologic Dispensary № 2&quot; Health Department of Krasnodar Area</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei Horinko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution &quot;Perm Regional Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Petr Krivorotko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.N. Petrov Oncology Research Center of the Ministry of Health of the Russian Federation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yulia Shapovalova, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Non-governmental healthcare institution &quot;Chelyabinsk Road Clinical Hospital&quot; JSC &quot;Russian Railways&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ludmila Sheveleva, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution &quot;Volgograd Regional Clinical Oncology Dispensary № 1&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vadim Shirinkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>State Health Care Institution &quot;Orenburg Regional Clinical Oncology Dispensary&quot;</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shekar Patil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bangalore Institute of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prasad Narayanan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mazumdar Shaw Cancer Center and Narayana Hrudayalaya Multispecialty Hosptial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nalini Kilara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.S.Ramaiah Memorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergei Kulik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Donetsk City Municipal Oncology Dispensary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Igor Sedakov, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Donetsk Regional oncology centers</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrei Rusin, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zakarpatskii Regional Clinical Oncology Dispensary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yuri Vinnik, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kharkiv Regional Clinical Oncology Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergei Odarchenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vinnitskii Regional Oncology Dispensary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HCG Bangalore Institute of Oncology</name>
      <address>
        <city>Bangalore</city>
        <zip>560027</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.S.Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.S.Ramaiah Memorial Hospital</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk District Clinical Oncology Dispensary</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital at Chelyabinsk Railway Station</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State public health institution &quot;Regional Oncology Dispensary №1&quot;</name>
      <address>
        <city>Engels</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State public health institution &quot;Republican Clinical Oncology Dispensary&quot; of the Ministry of Health of the Republic of Tatarstan</name>
      <address>
        <city>Kazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Oncology Dispensary N1</name>
      <address>
        <city>Krasnodar</city>
        <zip>350040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Health Care Institution &quot;Moscow City Oncology Hospital № 62&quot; Moscow Health Department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-governmental healthcare institution &quot;Central Clinical Hospital № 2 Semashko&quot; JSC &quot;Russian Railways&quot;</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State public health institution &quot;Nizhny Novgorod Regional Oncology Dispensary&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State budget healthcare institution Omsk region &quot;Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Omsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Health Care Institution &quot;Orenburg Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perm Region Oncology Dispensary</name>
      <address>
        <city>Perm</city>
        <zip>614066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pyatigorsk Oncology Center</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357502</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Educational Institution of Higher Professional Education &quot;Mordovia State University N.P. Ogareva &quot;</name>
      <address>
        <city>Saransk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Health Care Institution &quot;Oncologic Dispensary № 2&quot; Health Department of Krasnodar Area</name>
      <address>
        <city>Sochi</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>N.N.Petrov Oncology Research Center</name>
      <address>
        <city>St.Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy named after S.M. Kirov</name>
      <address>
        <city>St.Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution health care &quot;Tula Regional Oncology Dispensary&quot;</name>
      <address>
        <city>Tula</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State public health institution &quot;Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Ulyanovsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volgograd Regional Oncology Dispensary №3</name>
      <address>
        <city>Volgograd</city>
        <zip>404130</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Health Care Institution &quot;Volgograd Regional Clinical Oncology Dispensary № 1&quot;</name>
      <address>
        <city>Volgograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State public health institution &quot;Voronezh Regional Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donetsk City Oncology Dispensary</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Donetsk Regional Antitumor Center</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv Regional Clinical Oncology Center</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zakarpatskyi Regional Clinical Oncology Center</name>
      <address>
        <city>Uzhhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsia Regional Clinical Oncology Dispensary</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>empegfilgrastim</keyword>
  <keyword>pegylated filgrastim</keyword>
  <keyword>neutropenia</keyword>
  <keyword>febrile neutropenia</keyword>
  <keyword>chemotherapy-associated neutropenia</keyword>
  <keyword>breast cancer</keyword>
  <keyword>docetaxel</keyword>
  <keyword>doxorubicin</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
